JP2023550287A5 - - Google Patents
Info
- Publication number
- JP2023550287A5 JP2023550287A5 JP2023526513A JP2023526513A JP2023550287A5 JP 2023550287 A5 JP2023550287 A5 JP 2023550287A5 JP 2023526513 A JP2023526513 A JP 2023526513A JP 2023526513 A JP2023526513 A JP 2023526513A JP 2023550287 A5 JP2023550287 A5 JP 2023550287A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- amino acid
- sap
- protein according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108799P | 2020-11-02 | 2020-11-02 | |
| US63/108,799 | 2020-11-02 | ||
| US202163153777P | 2021-02-25 | 2021-02-25 | |
| US63/153,777 | 2021-02-25 | ||
| PCT/US2021/072168 WO2022094630A1 (en) | 2020-11-02 | 2021-11-01 | Sap fc fusion proteins and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023550287A JP2023550287A (ja) | 2023-12-01 |
| JP2023550287A5 true JP2023550287A5 (enExample) | 2024-11-11 |
| JP7856264B2 JP7856264B2 (ja) | 2026-05-11 |
Family
ID=78771272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526513A Active JP7856264B2 (ja) | 2020-11-02 | 2021-11-01 | Ｓａｐ ｆｃ融合タンパク質及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12161692B2 (enExample) |
| EP (1) | EP4237083A1 (enExample) |
| JP (1) | JP7856264B2 (enExample) |
| KR (1) | KR20230097061A (enExample) |
| AU (1) | AU2021368272A1 (enExample) |
| BR (1) | BR112023008317A2 (enExample) |
| CA (1) | CA3196766A1 (enExample) |
| IL (1) | IL302388A (enExample) |
| MX (1) | MX2023005063A (enExample) |
| WO (1) | WO2022094630A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| BR112023008317A2 (pt) | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
| WO2024153768A1 (en) * | 2023-01-20 | 2024-07-25 | Boehringer Ingelheim International Gmbh | Il-12 fc fusion proteins |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317120D0 (en) | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
| AU2002225772A1 (en) | 2000-11-27 | 2002-06-03 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| US9200079B2 (en) * | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| HUE041034T2 (hu) | 2009-06-17 | 2019-05-28 | Promedior Inc | SAP-variánsok és alkalmazásuk |
| WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| WO2013096847A1 (en) | 2011-12-21 | 2013-06-27 | Promedior, Inc. | Serum amyloid p-antibody fusion proteins |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
| US10213506B2 (en) | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| US20200148779A1 (en) | 2017-05-25 | 2020-05-14 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| JP2021521273A (ja) | 2018-04-12 | 2021-08-26 | メディアファーマ エス．アール．エル． | Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用 |
| BR112023008317A2 (pt) | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
-
2021
- 2021-11-01 BR BR112023008317A patent/BR112023008317A2/pt unknown
- 2021-11-01 MX MX2023005063A patent/MX2023005063A/es unknown
- 2021-11-01 WO PCT/US2021/072168 patent/WO2022094630A1/en not_active Ceased
- 2021-11-01 KR KR1020237016378A patent/KR20230097061A/ko active Pending
- 2021-11-01 EP EP21815085.2A patent/EP4237083A1/en active Pending
- 2021-11-01 JP JP2023526513A patent/JP7856264B2/ja active Active
- 2021-11-01 US US17/516,601 patent/US12161692B2/en active Active
- 2021-11-01 CA CA3196766A patent/CA3196766A1/en active Pending
- 2021-11-01 IL IL302388A patent/IL302388A/en unknown
- 2021-11-01 AU AU2021368272A patent/AU2021368272A1/en active Pending
-
2024
- 2024-10-25 US US18/927,701 patent/US20250152667A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500015A5 (enExample) | ||
| JP2023506765A5 (enExample) | ||
| JP2023509212A5 (enExample) | ||
| CN110511280B (zh) | 一种透皮重组纤连蛋白及其应用 | |
| JP2021121642A (ja) | 二特異性抗体基幹 | |
| JP2023528207A5 (enExample) | ||
| JP5077924B2 (ja) | 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物 | |
| JP2001514858A5 (enExample) | ||
| Li et al. | Apamin as a novel template for structure-based rational design of potent peptide activators of p53 | |
| JP2020506898A5 (enExample) | ||
| JP2023553697A5 (enExample) | ||
| JP2008500373A5 (enExample) | ||
| JP2012505403A5 (enExample) | ||
| JP2017529059A5 (enExample) | ||
| JP2010534486A5 (enExample) | ||
| JP2023545707A5 (enExample) | ||
| JP2023554379A5 (enExample) | ||
| JP2024507540A5 (enExample) | ||
| US20170037109A1 (en) | Fibronectin Binding Domains with Reduced Immunogenicity | |
| JP2025504625A5 (enExample) | ||
| JP2024504923A5 (enExample) | ||
| JP2024544559A5 (enExample) | ||
| JP2020535811A5 (enExample) | ||
| JP2014517690A5 (enExample) | ||
| JP2024023268A5 (enExample) |